---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-059398"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:34:52.543478+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Benitec reports durable improvements in swallowing function with BB-301 in OPMD interim results

## Summary
- Three subjects treated with low-dose BB-301 showed significant, clinically meaningful improvements in swallowing function at 12 months (Subjects 1,2) and 3 months (Subject 3) post-treatment.
- Subject 1: 41% reduction in SSQ total symptom burden at 12 months; VFSS showed reductions in pharyngeal residue across all food and liquid consistencies.
- Subjects 2 and 3: near-complete resolution of pathologic sequential swallows; Subject 2 achieved clinically normal SSQ (68 units) at 12 months, Subject 3 at 3 months (70 units).
- No severe adverse events reported; five subjects safely treated; sixth and final Cohort 1 subject expected to receive low-dose BB-301 in Q2 2025.

## SEC filing metadata
- accession: 0001193125-25-059398
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312525059398/0001193125-25-059398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312525059398/d906340d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-059398
- JSON: https://secwatch.observer/filing/0001193125-25-059398.json
- Plain text: https://secwatch.observer/filing/0001193125-25-059398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.